BRAF and colorectal carcinoma: These treatments are recapitulated using organoids from BRAF-V600E-mutant mouse models.10 Our findings suggest that chemotherapy and targeted therapy are non–cross-resistant and induce quite distinct selection pressures in BRAF-V600E-mutant CRC.